Mechanistically, using a combination of in vitro assays, an in vivo preclinical model of PDAC and patient-derived tumour explants, we provide evidence that inhibition of IGF signalling promotes TAM/CAF production of the T cell chemokines CXCL9 and CXCL10 leading to an increase in CD8+ T cell recruitment and trafficking towards the pancreatic TME. This evidence concerns the gene CXCL9 and neoplasm.